Untitled

Garin, L.; Corbinais, Stéphane; Boucher, Éveline; Blanchot, J.; Guilcher, Patrick Le; Raoul, Jean‐Luc

doi:10.1023/a:1021065407822

Cited by 28 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a review of surgeries performed on patients with a GCC, a simple appendectomy was performed in 24.57% of the cases and right hemicolectomy in 34.7% of the cases [ 7 ]. The treatment modality for a GCC with peritoneal seeding is also controversial, but recent reports advocate cytoreductive surgery (CRS) followed by intraperitoneal chemotherapy [ 8 , 9 , 10 , 11 ]. Our patient initially showed a peritoneal cancer index (PCI) of 30, and he showed completeness of cytoreduction of CC2.…”

Section: Discussionmentioning

confidence: 99%

Peritoneal Metastatic Goblet-Cell Carcinoid Tumor Treated With Cytoreductive Surgery and Intraperitoneal Chemotherapy

et al. 2015

View full text Add to dashboard Cite

We report a case of a goblet-cell carcinoid tumor of the appendix which metastasized to the peritoneum and was treated by using cytoreductive surgery (CRS) with intraperitoneal chemotherapy. A 47-year-old male presented with chronic constipation and was diagnosed as having a rectal adenocarcinoma with a signet-ring-cell component under colonoscopy. Computed tomography suggested peritoneal metastases with diffuse nodular parietal peritoneal thickening of the entire abdomen and focal invasion of the upper rectum by a seeding mass. CRS with intraperitoneal chemotherapy was done under the diagnosis of a rectal adenocarcinoma with peritoneal metastases. The pathologic diagnosis was a goblet-cell carcinoid tumor of the appendix with peritoneal metastasis. The histological discrepancy between a peritoneal metastatic mass and a rectal mass was due to the mixed histological pattern of a goblet-cell carcinoid tumor. A metastatic mass may not share identical immunohistochemical characteristics from its origin. This histologic discrepancy necessitates caution in diagnosing a distant metastasis of a goblet-cell carcinoid tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Peritoneal Metastatic Goblet-Cell Carcinoid Tumor Treated With Cytoreductive Surgery and Intraperitoneal Chemotherapy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Debulking surgery with adjuvant intraperitoneal chemotherapy may improve survival in some patients with disseminated disease [2, 6, 12, 13]. …”

Section: Discussionmentioning

confidence: 99%

Appendiceal Goblet Cell Carcinoid Tumour: A Case of Unexpected Lung Metastasis

et al. 2012

View full text Add to dashboard Cite

Goblet cell carcinoid tumours are often considered a subset of appendiceal neuroendocrine tumours which behave more aggressively. They usually metastasize through transcoelomic/peritoneal invasion and common sites include the ovaries, peritoneum, and liver. Metastases may have goblet cell carcinoid, signet ring cell carcinoma or classic carcinoid histology. We report the first case in the literature of a patient with a goblet cell carcinoid with lung metastasis, which was associated with unfavourable outcome.

show abstract

“…These tumors are generally considered to be refractory to 5-FU-based chemotherapy. However, there is at least one case report of a patient with metastatic adenocarcinoid (histological features of both adenocarcinoma and carcinoid) demonstrating a complete and persistent response to FOLFOX-4 [6]. There is also a case report of a patient with hybrid histology (features of both disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis) and pseudomyxoma peritonei, previously treated with cytoreduction and intraperitoneal hyperthermic chemotherapy, demonstrating an objective response to capecitabine [7].…”

Section: Discussionmentioning

confidence: 99%

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab

et al. 2009

View full text Add to dashboard Cite

A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type. CT scan postoperatively revealed gross residual disease. The patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT scan showed a decrease in residual disease and the patient clinically improved. After her treatment has been continued for 13 months, she remains clinically well and her CT scan shows sustained disease stability. Disseminated appendiceal carcinoma is generally considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is the first reported case of a patient with appendiceal adenocarcinoma demonstrating clinical benefit and sustained stability of disease with combination chemotherapy plus bevacizumab.

show abstract

Untitled

Cited by 28 publications

References 7 publications

Peritoneal Metastatic Goblet-Cell Carcinoid Tumor Treated With Cytoreductive Surgery and Intraperitoneal Chemotherapy

Peritoneal Metastatic Goblet-Cell Carcinoid Tumor Treated With Cytoreductive Surgery and Intraperitoneal Chemotherapy

Appendiceal Goblet Cell Carcinoid Tumour: A Case of Unexpected Lung Metastasis

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab

Contact Info

Product

Resources

About